Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980134 | 0.81 | POLB (0.39) | CASP3ALDH1A1TTRCES1CYP1A2 | |
| SCHEMBL29583687 | 0.78 | CASP3 (0.40) | CASP3ALDH1A1TTRCES1CYP1A2 | |
| SCHEMBL17059740 | 0.77 | MAPK7 (0.42) | CASP3ALDH1A1TTRCES1SMN1; SMN2 | |
| SCHEMBL10098691 | 0.75 | MAPK7 (0.56) | TTRCES1MAPK7BRD4DCLK1 | |
| SCHEMBL11486350 | 0.74 | ALDH1A1 (0.55) | ALDH1A1CYP1A2SMN1; SMN2AKT1 | |
| SCHEMBL21938134 | 0.73 | DCLK1 (0.68) | MAPK7BRD4DCLK1PIK3CDAURKA | |
| SCHEMBL20628525 | 0.72 | AURKA (0.69) | MAPK7BRD4DCLK1PIK3CDAURKA | |
| SCHEMBL10098692 | 0.72 | MAPT (0.41) | CASP3ALDH1A1JUNNFKB1NFKB2 | |
| SCHEMBL16065742 | 0.72 | MAPK7 (0.45) | CASP3ALDH1A1JUNNFKB1NFKB2 | |
| SCHEMBL20628496 | 0.71 | DCLK1 (0.38) | MAPK7BRD4DCLK1PIK3CDAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECH LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4479400-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | Cancer Research Technology Limited (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| EP-4229061-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMC2, PSMA6 | CASP3 2292/4885ALDH1A1 3527/4885JUN 1911/4885 |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | MAP3K5, MAPK1, MAP3K20 | CASP3 2980/4885ALDH1A1 798/4885JUN 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.